FDA panel to review NSAIDs this month

Share this article:

An FDA advisory panel convenes in six days to consider revoking the over-the-counter status of some NSAIDs. Drugstore News reports that the group will meet February 10 to discuss the risks these drugs may pose to heart health. DSN says the group will also discuss whether Pfizer should continue its Celebrex safety study which compares the arthritis pain reliever to ibuprofen and naproxen, since naproxen is considered safer.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters